Imatinib (trade name Gleevec and Glivec) is an inhibitor of tyrosine kinases including Bcr-Abl and just one of the many drugs covered in Thomson Reuters Cortellis for Competitive Intelligence. In the Drug Report below you will see the drug overview information, news, deals, development status, literature evaluations, SWOT analysis, patent position and sales and market share data, all of which is shown in Cortellis for Competitive Intelligence, in fact there are over 40,000 of these Drug Reports in Cortellis for Competitive Intelligence.

Cortellis for Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma TM and Thomson Reuters Partnering TM (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

All Cortellis for Competitive Intelligence content is subject to an exhaustive editorial review process conducted by scientists, Pharma professionals, regulatory experts, and generics specialists. It is also updated regularly, so you get the most accurate and up-to-date information on the pharmaceutical data that matters to you.

Take a two week trial of Cortellis for Competitive Intelligence and see what it can do for you.